At a glance
ClinicalIndex Comparison RecordN/ACompleted· 83 enrolled
Drug / intervention
B. subtilis R0179 +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Bacillus Subtilis R0179 in Capsules on Gastrointestinal Survival, Transit Time, Gastrointestinal Symptoms, and General Wellness in Healthy Young Adults
In Brief
A clinical study evaluating B. subtilis R0179 and Placebo for Healthy. Completed, enrolled 83 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effect of three doses of the probiotic B. subtilis (Bacillus subtilis R0179) delivered in capsules on gastrointestinal and general wellness in healthy young adults, survival through the gastrointestinal tract and impact on intestinal microbes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLallemand Human Nutrition
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
Primary CompletionOct 2012
First PostedMar 2013
TodayJul 2026
First PostedMar 1, 2013
Enrollment StartJul 1, 2012
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.3 years ago
Interventions
B. subtilis R0179dietary
B. subtilis R0179 for a period of 4 weeks. One capsule per day.
Placebodietary
Placebo (starch, magnesium stearate, citric acid) capsules for a period of 4 weeks. One capsule per day.